drugset / Trial / NCT04572867

Aquapheresis Efficacy in Outpatients With Decompensated Heart Failure

NCT04572867

Withdrawn Ramona Gelzer Bell
RandomizedParallel-groupOpen-labelTreatment

Summary

With this research the Investigators hope to learn if early aquapheresis in an outpatient setting will improve congestive heart failure symptoms in outpatients with decompensated heart failure who have been refractory to high dose diuretics. In previous trials in inpatient settings, aquapheresis has been demonstrated to improve quality of life and reduce hospital visits for those who have undergone the treatment. This study is one of the first to evaluate the effectiveness of aquapheresis in veterans with congestive heart failure in an outpatient setting. The aquapheresis device, Aquadex FlexFlow® System, manufactured by CHF Solutions™, Minneapolis, MN, has been approved by the Food and Drug Administration (FDA) for removing excess sodium and fluid from patients suffering from volume overload, like in congestive heart failure.

Timeline

Start
2021-06-08
Primary completion
2021-07-27
Completion
2021-07-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bumetanide Small molecule 8 mg Intravenous
Comparator Furosemide Other / unclassified 320 mg Intravenous
Comparator Metolazone Small molecule 2.5 mg Oral
Comparator Metolazone Small molecule 5 mg Oral